PARK CITY, Utah — Suprachoroidal drug delivery for uveitic macular edema provides durable effects in real-world settings, matching those of phase 3 clinical trials, according to a speaker at Clinical Trials at the Summit.
An optimal injection technique is key to successful treatment, Glenn C. Yiu, MD, PhD, said.
In the phase 3 PEACHTREE trial, suprachoroidal triamcinolone acetonide for uveitic macular edema (UME) showed sustained visual gains over 24 weeks and low rates of rescue after injections at day 0 and week 12. A real-world study based on IRIS Registry data found similar outcomes